The one-year cost of targeted therapy for rectal cancer is about 50,000 dollars, and there is a certain gap between different drugs and medication programs.
Rectal cancer belongs to the more common malignant tumors in clinic, for the advanced ones that cannot be surgically removed or have recurrence and metastasis after surgery, targeted therapy can be considered, such as bevacizumab, regorafenib and furaquintinib.
Most of the targeted therapies have become routine treatments, and some of them are within the scope of medical reimbursement, so it greatly reduces the financial pressure of patients. For some patients who need to undergo new targeted therapy drugs, which may be more expensive or even not available for sale in China, such patients should choose the appropriate targeted drugs according to the specific situation.
It is recommended that patients choose the appropriate treatment according to their own situation under the guidance of their doctors, and the drugs should be used under the guidance of their doctors.